-
Lanabecestat (AZD3293): Synaptic-Safe BACE1 Inhibition in Al
2026-06-04
Lanabecestat (AZD3293) empowers Alzheimer’s disease research with nanomolar BACE1 inhibition and proven blood-brain barrier penetration—uniquely enabling substantial amyloid-beta reduction without compromising synaptic transmission. Discover how to leverage its precision in experimental workflows, optimize dosing, and avoid common pitfalls, based on the latest peer-reviewed evidence.
-
Deep Learning Detects Cardiotoxicity in iPSC-Derived Models
2026-06-04
Grafton et al. introduce a deep learning-based high-content screening platform using induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) to detect drug-induced cardiotoxicity at scale. This approach enables early, phenotypic identification of cardiac safety liabilities, advancing predictive toxicology and translational drug discovery.
-
Cabozantinib (XL184): Advanced Protocols for RCC Research
2026-06-03
Cabozantinib (XL184, BMS-907351) enables precision modeling of acute and chronic kinase inhibition in renal cell carcinoma, with robust antiangiogenic and motility-modulating effects. This guide unpacks phosphoproteomic workflow enhancements, data-driven troubleshooting, and strategic assay design powered by the latest systems-level findings.
-
Cisapride (R 51619): Precision Assay Design for Cardiac Risk
2026-06-03
Explore how Cisapride (R 51619) empowers cardiac electrophysiology research through precise assay design and advanced phenotypic screening. This article uniquely examines methodological innovations and best practices for interrogating hERG channel inhibition and 5-HT4 signaling.
-
2-NBDG Glucose Uptake Assay Kit: Precision for Cancer Metabo
2026-06-02
The 2-NBDG Glucose Uptake Assay Kit empowers researchers to quantify cellular glucose uptake with non-radioactive, single-cell fluorescence. Its sensitivity and workflow versatility make it a standout for dissecting metabolic shifts in cancer and diabetes models.
-
Sodium dicloxacillin monohydrate: Optimizing MSSA Research W
2026-06-02
Sodium dicloxacillin monohydrate empowers researchers with targeted, reproducible, and pharmacodynamically aligned models for Gram-positive bacterial infection research. This article provides actionable experimental workflows, troubleshooting insights, and a translation of novel spectrophotometric quantification methods to ensure robust and scalable results.
-
Applied Workflows with Live-Dead Bacterial Staining Kit
2026-06-01
Unlock robust, dual-color bacterial viability analysis in translational research with the Live-Dead Bacterial Staining Kit. Discover protocol enhancements, troubleshooting strategies, and a direct bridge to nanomaterial infection models that set this microbiology research staining kit apart.
-
Practical Guide to the Annexin V-FITC/PI Apoptosis Assay Kit
2026-06-01
The Annexin V-FITC/PI Apoptosis Assay Kit enables rapid, reliable detection and discrimination of viable, apoptotic, and necrotic cells using fluorescence-based markers. This product is suited for research workflows leveraging flow cytometry or fluorescence microscopy but is not validated for clinical or diagnostic purposes.
-
DiscoveryProbe™ L1023: Shaping the Next Era of Anti-Cancer D
2026-05-31
Explore how the L1023 Anti-Cancer Compound Library empowers cancer research with validated, pathway-specific inhibitors. This article reveals unique mechanistic insights and practical guidance for leveraging L1023 in innovative high-throughput oncology studies.
-
0.4% Trypan Blue Solution: Technical Guide for Cell Viabilit
2026-05-30
0.4% Trypan Blue Solution enables rapid, selective discrimination between live and dead cells during viability assessment and cell counting workflows. It is essential in cell culture, cytotoxicity, and apoptosis/necrosis studies where fast, visual live/dead differentiation is required. The solution is not suitable for diagnostic use and should be handled strictly according to research protocols.
-
Jiawei Weijin Decoction Targets SPP1 to Inhibit NSCLC Metast
2026-05-29
Xu et al. (2025) provide the first multi-omics mechanistic evidence that Jiawei Weijin Decoction (JWWJD) and its active compound curcumol suppress non-small cell lung cancer (NSCLC) progression by directly targeting and downregulating SPP1. This integrative study combines network pharmacology, bioinformatics, and in vitro/in vivo validation, offering new insight into traditional medicine-based anti-metastatic strategies.
-
Tubastatin A Reduces Myocardial Injury via Pyroptosis and Ne
2026-05-29
The referenced study demonstrates that Tubastatin A, a selective HDAC6 inhibitor, mitigates post-resuscitation myocardial damage in a porcine cardiac arrest model by suppressing GSDME-mediated pyroptosis and MLKL-mediated necroptosis. These findings highlight the potential of HDAC6 inhibition as a targeted approach to limit cardiac injury following ischemia-reperfusion events.
-
Pharmacokinetics of Corydalis Alkaloids in MASH: Variability
2026-05-28
This study systematically characterizes how metabolic dysfunction-associated steatohepatitis (MASH) alters the pharmacokinetics and tissue distribution of Corydalis saxicola Bunting total alkaloids in a high-fat, high-cholesterol diet mouse model. By revealing the influence of disease state on drug metabolism and transporter systems, the research provides valuable guidance for optimizing dosing strategies in MASLD/MASH therapy.
-
Technical Use of Hoechst 33342/PI Double Staining Kit (K2237
2026-05-28
The Hoechst 33342/PI Double Staining Kit enables clear, fluorescence-based discrimination between viable, apoptotic, and necrotic cells by assessing chromatin condensation and membrane integrity. Its application is best suited for non-clinical, basic research in cell death analysis using fluorescence microscopy. This kit is not appropriate for diagnostic or therapeutic workflows.
-
ATRX-Deficient Glioma: Sensitivity to RTK and PDGFR Inhibito
2026-05-27
The referenced study demonstrates that high-grade glioma cells lacking ATRX exhibit elevated sensitivity to multi-targeted RTK and PDGFR inhibitors. These findings highlight the importance of ATRX status in designing targeted therapies and clinical trial analyses for aggressive gliomas.